News

Dainippon Sumitomo in up to $315 million deal with Intercept for liver disease drug obeticholic

31-03-2011

Japanese drug major Dainippon Sumitomo Pharma (4506:JP) has entered into an exclusive licensing agreement…

Asia-PacificDainippon Sumitomo PharmaIntercept PharmaceuticalsLicensingobeticholic acidPharmaceutical

Back to top